ProCE Banner Activity

Therapeutic Relevance of HER3 in EGFR TKI-Resistant NSCLC


Download these slides from an expert-led webinar on the scientific rationale for targeting HER3 in NSCLC

Released: April 03, 2023



Yasushi Goto

Yasushi Goto, MD, PhD

Assistant Chief 
Department of Thoracic Oncology 
National Cancer Center Hospital Japan
Tokyo, Japan 

Provided by

ProCE Banner


This activity is supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Yasushi Goto, MD, PhD: consultant/advisor/speaker: Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Lilly, Merck, MSD, Novartis, Ono, Pfizer, Thermo Fisher; research grants (paid to institution): AbbVie, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Kyorin, Novartis, Ono, Pfizer, Preferred Network; research grants (paid to clinical trial group): AZK, Pfizer; advisory board: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Guardant Health, Illumina, Lilly, MSD, Novartis, Ono, Pfizer, Taiho.